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Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is 
the most common monogenic cause of kidney failure, occur-
ring in more than 1 in 400 to 1,000 live births and accord-
ingly representing a major socioeconomic medical problem 
globally1. ADPKD arises owing to mutations in the PKD1 gene 
(about 85% of cases) or the PKD2 gene (about 15% of cases), 
which encode the proteins polycystin-1 (PC1) and -2 (PC2), 
respectively2,3. Compared with patients who have PKD1 muta-
tions, those with PKD2 mutations have a milder phenotype and 
reach end-stage renal disease (ESRD) about 20 years later4–6. 
ADPKD is characterized by progressive development and 
enlargement of cysts in all nephron segments but preferentially 
in the collecting duct, and ESRD occurs in 50% of patients by 
the age of 60 years1. It is associated with cyst formation in other 
organs, primarily the liver and pancreas, and with cardiovascular 
anomalies such as intracranial arterial aneurysms and vascular 
dissections. Huge variation is observed in disease phenotype 
and progression, even within families; the reason for this is 
poorly understood, but genetic modifiers, including hypomorphic 
alleles, probably play a significant role.
Although a definitive curative treatment is not currently avail-
able, there is a disease-modifying therapy using a V2 receptor 
antagonist (tolvaptan)7,8. This article guides the reader through 
recent achievements, and the clinical consequences, within 
the field of ADPKD.
Genetics and genetic testing
Mutations in other genes, such as GANAB and DNAJB11, have 
recently been identified in a small subgroup of patients9,10, 
but the phenotypes related to these mutations are not exactly 
the same as those caused by mutations in PKD1 or PKD2. This 
may suggest that, instead of using the name “ADPKD”, it 
would be appropriate to name these diseases after the mutated 
gene, as has been done, for example, for ADTKD11. Whereas 
mutations in GANAB give rise to a mild form of cystic disease 
that does not progress to ESRD9, mutations in DNAJB11 cause 
cystic disease in the context of which ESRD may develop in 
the absence of marked kidney enlargement10.
Genetic testing has undergone remarkable progress, as is very evi-
dent if one considers the case of ADPKD. When the PKD1 and 
PKD2 genes were first identified, genetic testing was performed 
by means of linkage analysis5. Not only was this time consum-
ing but also, more importantly, several affected and non-affected 
family members were needed in order to identify the risk 
haplotype. As soon as the PKD1 gene was identified, it became 
evident that genetic testing for the gene would be burden-
some owing to the large transcript size (>14 kb) and reiteration 
of the genomic area encoding about 75% of the protein on the 
same chromosome12. The group of Harris then developed a 
technique that used long-range polymerase chain reaction and 
benefited from the few non-repeated nucleotides13. Although 
this allowed diagnosis of a single individual, it remained time 
consuming and was also expensive. Over the past 3 years, next- 
generation sequencing (NGS) has changed the scenario14–16. 
The use of NGS for genetic diseases such as ADPKD has reduced 
costs, improved sensitivity, and reduced turnaround time17,18. 
A further advantage of this relatively new technique is that gene 
panels or whole exome sequencing can be used, allowing the 
detection of mutations in ultrarare genes that account for a 
very small number of cases of renal cystic disease17. The draw-
back of testing PKD1 is the huge number of variants of unknown 
significance (VUSs) that can be identified, around 10 per 
patient18. Some of these VUSs have previously been published as 
mutations, but for many pathogenicity is still to be elucidated19. 
This is of the utmost relevance when a patient seeks preimplan-
tation genetic diagnosis (PGD) or when a disease-modifying 
treatment for ADPKD can be offered but there is uncertainty 
over the diagnosis. PGD has evolved over recent years to 
become a valuable technique to offer patients with severe genetic 
diseases, although there are ethical issues regarding its use for 
non-severe genetic diseases. ADPKD is halfway between these 
categories, and genetic counseling is highly recommended 
to ensure sound understanding of the pros and cons of such a 
procedure20. Probably, each case or family should be counseled 
differently according to the severity of the disease, but patient 
attitudes to PGD vary considerably depending on how well the 
family is dealing with the disease, religious aspects, age, disease 
severity, and so on.
Progression of autosomal dominant polycystic 
kidney disease
A large number of factors have been identified as influencing 
disease progression21, and whereas some are modifiable, many 
are not22. Among the latter are male sex, PKD1 mutations (worse 
if protein-truncating (PT)), early development of renal symp-
toms, early detection of high blood pressure23, and large kidney 
volumes in relation to age and height24,25. Modifiable factors that 
should be highlighted in patients with ADPKD include smoking; 
blood pressure; lipid levels; water, protein, and calorie intake; 
and body mass index (BMI)26–31. Also, some biomarkers, such as 
MCP-1, FGF23, and copeptin, have been found to be predictive 
factors of ADPKD progression32–34.
The prediction of which patients will have a rapid progression 
is crucial not only for the decision of whether to use a disease-
modifying drug but also for the recruitment of patients to clini-
cal trials35. Although in the past few years many attempts have 
been made to provide tools predictive of rapid disease progres-
sion, to date there is no gold standard. Some of these predictive 
tools employ imaging; an example is the Mayo Clinic ADPKD 
calculator, which uses the height-adapted total kidney volume 
(htTKV) to classify patients into one of five classes (A–E) on the 
basis of growth rates: less than 1.5%, 1.5–3%, 3–4.5%, 4.5–6%, 
or more than 6% per year36. Measuring TKV for use as a prog-
nostic biomarker does not require high precision. Measurement by 
the ellipsoid equation as well as by means of various imaging 
modalities is possible27,37. Another imaging approach that can be 
used to predict PKD progression involves the measurement of 
renal length. Bhutani et al. demonstrated that a renal diameter of 
16.8 cm is predictive of chronic kidney disease (CKD) stage 3 
within 8 years38. An alternative to imaging-based prognostic 
strategies is the Predicting Renal Outcome in Polycystic Kidney 
Disease (PROPKD) scoring system, as shown in a large cohort 
from Brittany, France23. This scoring system uses both clinical 
and genetic data to stratify risk of disease progression. Patients 
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may reach a score suggestive of rapid progression if they have 
hypertension or early urinary symptoms before the age of 
35 years plus a PT mutation. Male sex is also included in the 
scoring system. Obvious drawbacks of this predictive tool are 
the need to perform genetic testing, which may not be avail-
able in many centers, and the impossibility of employing it in 
patients younger than 35 who are asymptomatic. In addition, 
it is subject to the need to establish a relationship between 
early symptoms and ADPKD and the limitation that many 
rapid progressors with PT mutations do not develop early 
symptoms.
The European Renal Association-European Dialysis and Trans-
plant Association (ERA-EDTA) Working Groups on Inherited 
Kidney Disorders and European Renal Best Practice (WGIKD/
ERBP) developed a hierarchical decision-making algorithm that 
may offer guidance on the identification and prediction of rapid 
disease progression in patients with ADPKD and subsequently 
identify candidates for tolvaptan treatment39. When this algorithm 
was tested in a cohort of 305 patients, it was found that 15.7% 
fulfilled the ERA-EDTA criteria and that the overall propor-
tion of patients with rapid progression rose to 27% upon incor-
poration of expanded criteria based on data from the REPRISE 
(Replicating Evidence of Preserved Renal Function: an Inves-
tigation of Tolvaptan Safety and Efficacy in ADPKD) trial40 
(that is, age of less than 56 years and estimated glomerular 
filtration rate [eGFR] of more than 30 mL/min/m2)41. This study, 
together with a recent assessment of an unpublished large series 
of patients, calls into question the suitability of the algorithm, 
especially in its first steps when limiting for age/eGFR and 
using retrospective eGFR. Each country, even region, in Europe 
has either approved the use of the drug on these terms or pro-
posed some changes. For example, the National Institute for 
Health and Care Excellence (NICE) decision in the UK was to 
treat on the basis of these criteria but only patients with CKD 
stage 2 to 3 without limiting age, whereas in Scotland they 
approved its use in stage 1. In the US, the preferred approach 
for definition of a rapid progressor is based on htTKV, age, 
and eGFR, basically using the Mayo ADPKD calculator42. 
Risk assessment in ADPKD is an evolving process 
that will undergo further refinement as new clinical data are 
obtained and prediction tools are developed. The performance 
of risk assessment guidelines needs to be evaluated and 
validated by real-life clinical data, but it is probable that the 
use of a composite tool including age, renal function, imaging, 
family history and possibly genetic testing will be able to 
define rapid progression very accurately.
Basic renal protective measures
Based on the HALT-PKD (Halt Progression of Polycystic 
Kidney Disease) trial, the recommendations regarding blood 
pressure control for ADPKD were recently lowered26. The target 
should now be 95–110/60–75 mmHg in 15- to 49-year-old 
patients with an eGFR of more than 60 mL/min/1.73 m2. First-
line management of hypertension should include a blocker of 
the renin–angiotensin–aldosterone system (angiotensin-converting 
enzyme inhibitors and angiotensin-II receptor blockers)27. 
Second- and third-line treatments should be diuretics and 
beta-blockers. Calcium channel blockers (particularly the 
dihydropyridine class) should be considered if blood pressure is 
not controlled by the other agents27. The CRISP (Consortium for 
Radiologic Imaging Studies of Polycystic Kidney Disease) and 
HALT studies suggest that moderate dietary sodium restriction 
(2.3–3 g) be recommended to patients with ADPKD22.
In patients with cyst infection, a positron emission tomography/
computed tomography scan is recommended to enable deter-
mination of the location of cysts for the purpose of diagnosis 
or drainage43. Fluoroquinolones remain the first-line antibiotic 
treatment, but their side effects and the increasing prevalence of 
fluoroquinolone-resistant Gram-negative bacilli mean that cyst 
infections frequently represent a very large burden.
Until more information becomes available44,45, moderate enhance-
ment of hydration, spread out over the course of 24 hours, is 
recommended with the goal of maintaining an average urine 
osmolality of not more than 280 mOsm/L27,46.
Based on experimental studies and lessons learned from CKD 
in general, a daily protein intake of 0.8–1.0 g/kg ideal body 
weight seems appropriate in ADPKD27. Although protein-restricted 
diets are usually already low in phosphorus, patient educa-
tion on the need to avoid processed foods that contain readily 
absorbed inorganic phosphates is appropriate. Sodium bicarbo-
nate supplementation is recommended in order to treat metabolic 
acidosis, and the aim is to maintain the plasma bicarbonate 
level at a minimum of 22 mmol/L27.
Mild to moderate food restriction has been found to markedly 
reduce cystogenesis in animal models of PKD47,48. This fact, 
together with evidence that excess food intake has a detrimen-
tal effect both in PKD trials and in CKD in general, means that 
moderation of caloric intake and avoidance of an above-average 
BMIshould be recommended to patients with ADPKD29.
A small trial with statins in children has yielded positive 
results49, but a post-hoc analysis of the HALT-PKD trials failed 
to demonstrate a benefit of statin therapy on renal outcomes50. 
However, evidence in ADPKD22,31, and in CKD in general, 
indicates that it is appropriate to keep the low-density lipoprotein 
(LDL) cholesterol level at not more than 100 mg/dL.
Disease-modifying treatments
In the TEMPO (Tolvaptan Efficacy and Safety in Management 
of Autosomal Dominant Polycystic Kidney Disease and Its 
Outcomes) 3:4 trial, the vasopressin receptor antagonist tolvaptan 
was shown to slow the growth of cystic kidneys and the dete-
rioration of renal function7. Based on these results, the European 
Medicines Agency in 2015 approved tolvaptan to slow the 
progression of cyst development and renal insufficiency in ADPKD 
in adults with CKD stages 1–3 at initiation of treatment and 
evidence of rapidly progressing disease51. TEMPO 4:4 showed 
that benefit is sustained over time52.
In 2018, tolvaptan was approved by the US Food and Drug 
Administration for the purpose of slowing decline in kidney 
function in adults at risk of rapidly progressing ADPKD. This 
decision was based on additional information provided by the 
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REPRISE trial, which demonstrated slowing in the deterioration 
of renal function, even in the later stages of renal failure8.
Currently, more than 6,000 patients with ADPKD are being 
treated with tolvaptan around the world. However, tolvaptan 
does have side effects. It markedly impairs urinary concentrating 
ability and therefore patients experience polyuria, nocturia, 
and polydipsia7,8. In addition, a small proportion of patients 
develop liver function abnormalities; it appears that whereas some 
of these abnormalities can be significant, all resolve upon drug 
discontinuation53. This rare drug-induced liver injury led to 
the institution of a risk evaluation and mitigation strategy with 
monthly liver enzyme tests for the first 18 months and then at 
3-month intervals.
A few other drugs, such as mammalian target of rapamycin 
(mTOR) inhibitors, somatostatin analogues, and bosutinib, 
also underwent clinical trials but failed to show any positive 
effect on disease progression54–57. Recommendations for the 
management of ADPKD are shown in Figure 1.
Figure 1. Diagnosis and management of autosomal dominant polycystic kidney disease. ACE/ARB, angiotensin-converting 
enzyme/angiotensin receptor blocker; ADPKD, autosomal dominant polycystic kidney disease; BMI, body mass index; eGFR, 
estimated glomerular filtration rate; ERA-EDTA, European Renal Association-European Dialysis and Transplant Association; hTKV, 
height-adapted total kidney volume; HTN, hypertension; LDL, low-density lipoprotein; PROPKD, Predicting Renal Outcome in 
Polycystic Kidney Disease; Uosm, urine osmolality. Modified from Chebib et al.27 and Chebib et al.42.
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